ABSTRACT
Dyslipidemias include both rare single gene disorders and common conditions that have a complex underlying basis. In London, ON, there is fortuitous close physical proximity between the Lipid Genetics Clinic and the London Regional Genomics Centre. For >30 years, we have applied DNA sequencing of clinical samples to help answer scientific questions. More than 2000 patients referred with dyslipidemias have participated in an ongoing translational research program. In 2013, we transitioned to next-generation sequencing; our targeted panel is designed to concurrently assess both monogenic and polygenic contributions to dyslipidemias. Patient DNA is screened for rare variants underlying 25 mendelian dyslipidemias, including familial hypercholesterolemia, hepatic lipase deficiency, abetalipoproteinemia, and familial chylomicronemia syndrome. Furthermore, polygenic scores for LDL (low-density lipoprotein) and HDL (high-density lipoprotein) cholesterol, and triglycerides are calculated for each patient. We thus simultaneously document both rare and common genetic variants, allowing for a broad view of genetic predisposition for both individual patients and cohorts. For instance, among patients referred with severe hypertriglyceridemia, defined as ≥10 mmol/L (≥885 mg/dL), <1% have a mendelian disorder (ie, autosomal recessive familial chylomicronemia syndrome), ≈15% have heterozygous rare variants (a >3-fold increase over normolipidemic individuals), and ≈35% have an extreme polygenic score (a >3-fold increase over normolipidemic individuals). Other dyslipidemias show a different mix of genetic determinants. Genetic results are discussed with patients and can support clinical decision-making. Integrating DNA testing into clinical care allows for a bidirectional flow of information, which facilitates scientific discoveries and clinical translation.
Subject(s)
Dyslipidemias/genetics , Genetic Variation , Lipids/blood , Biomarkers/blood , DNA Copy Number Variations , Dyslipidemias/blood , Dyslipidemias/diagnosis , Dyslipidemias/history , Genetic Predisposition to Disease , Genetic Testing , High-Throughput Nucleotide Sequencing , History, 20th Century , History, 21st Century , Humans , Multifactorial Inheritance , Phenotype , Prognosis , Risk Assessment , Risk FactorsABSTRACT
The authors review more than three decades of progress in providing clinicians and patients with guidance on risk assessment, patient evaluation and cholesterol management. Beginning with the National Cholesterol Education Program's Initial Adult Treatment Panel report, the cholesterol guidelines increasingly reflect the progress made in understanding the benefits of improved lifestyle and nutrition to improve lipid profiles, major risk factors and reduce ASCVD risk. Moreover, they now provide qualitative and quantitative assessment tools to guide appropriate risk reduction LDL-C lowering therapy. Use of the Pooled Cohort Equations to determine Low, Borderline, Intermediate and High 10-year ASCVD risk is now joined by recognition of conditions and biomarkers that enhance ASCVD risk. This personalizes the risk discussion for the patient. An important addition is the selective use of coronary artery calcium (CAC) scoring to reclassify risk in patients at borderline or intermediate risk, but for whom a risk decision regarding statin therapy is uncertain. In secondary prevention, current guidelines provide criteria for determining a "very high" risk group in whom risk is especially high and in whom aggressive LDL-C lowering can be shown to provide increased absolute benefit. Current guidelines provide a comprehensive look at children and adolescents, young adults, elderly, women and issues specific to women through the life course. They provide guidance for those adults at risk due to severe hypercholesterolemia, persistent hypertriglyceridemia after secondary causes have been addressed, those with inflammatory disorders and HIV, those adults with chronic kidney disease, and those affected by issues of race/ethnicity. They conclude with a brief summary of recommendations emphasizing important concepts for providing safety with LDL-C lowering therapy. This combination of best external evidence and clinical expertise from the expert panel should provide a solid foundation for lipid management of patients at risk for or with clinical ASCVD.
Subject(s)
Anticholesteremic Agents/therapeutic use , Cardiovascular Diseases/prevention & control , Cholesterol/blood , Dyslipidemias/drug therapy , Evidence-Based Medicine , Practice Guidelines as Topic , Anticholesteremic Agents/adverse effects , Biomarkers/blood , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/epidemiology , Diffusion of Innovation , Dyslipidemias/blood , Dyslipidemias/epidemiology , Dyslipidemias/history , Evidence-Based Medicine/history , Evidence-Based Medicine/trends , Forecasting , History, 20th Century , History, 21st Century , Humans , Protective Factors , Risk Factors , Treatment OutcomeSubject(s)
Anticholesteremic Agents/history , Biomedical Research/history , Cardiology/history , Dyslipidemias/history , Proprotein Convertase 9/history , Serine Proteinase Inhibitors/history , Anticholesteremic Agents/therapeutic use , Clinical Trials as Topic/history , Dyslipidemias/drug therapy , Dyslipidemias/enzymology , Dyslipidemias/genetics , History, 20th Century , History, 21st Century , Humans , PCSK9 Inhibitors , Proprotein Convertase 9/genetics , Serine Proteinase Inhibitors/therapeutic useABSTRACT
This review tells the story of atherosclerosis research in the beginning of the 20th century. It presents the significance of cardiovascular diseases and addresses major questions currently being discussed among lipidologists and the current thinking with respect to low LDL-cholesterol levels and HDL. It provides an overview of the period during which lipid-modifying drugs were introduced and their relevance with respect to cardiovascular outcome data and lists possible reasons why some patients develop new cardiovascular events while being treated with statins. Especially impressive is the history of the appearance of the PCSK9 inhibitors on the market - only 12 years after PCSK9 was detected; a study completed in 2017 provides evidence about the cardiovascular effects of these new drugs. Other new drugs are also mentioned: mipomersen, lomitapide, and Alipogen Tiparvovec. Some promising drugs are still in the pipeline which inhibit the synthesis of apolipoprotein CIII, apolipoprotein(a), and the PCSK9 protein. During the 1970s, specific lipoprotein apheresis began to be used in high-risk patients with homozygous familial hypercholesterolemia, severe hypercholesterolemia and elevated Lipoprotein(a) levels and this review provides evidence of the effectiveness of the extracorporeal therapy with respect to the reduction of cardiovascular events. Particularly in patients with high Lipoprotein(a) levels, apheresis has been proven capable of reducing cardiovascular events by more than 80%. The current situation with regard to lipoprotein apheresis centers and patients in Germany is described herein, and, in conclusion, an estimation of the future of the therapeutic options in lipidology is given.
Subject(s)
Atherosclerosis/blood , Atherosclerosis/therapy , Blood Component Removal/methods , Dyslipidemias/blood , Dyslipidemias/therapy , Lipid Metabolism , Lipoproteins/blood , Animals , Atherosclerosis/diagnosis , Atherosclerosis/history , Biomarkers/blood , Blood Component Removal/adverse effects , Blood Component Removal/history , Drug Discovery/history , Dyslipidemias/diagnosis , Dyslipidemias/history , History, 20th Century , Humans , Hypolipidemic Agents/history , Hypolipidemic Agents/therapeutic use , Lipid Metabolism/drug effects , Lipoproteins/history , Treatment OutcomeSubject(s)
Biochemistry/history , Dyslipidemias/history , History, 20th Century , History, 21st Century , Humans , SpainSubject(s)
Atherosclerosis/history , Biomedical Research/history , Diet/history , Dyslipidemias/history , Hypolipidemic Agents/history , Lipids/history , Atherosclerosis/blood , Atherosclerosis/prevention & control , Diet/adverse effects , Dyslipidemias/blood , Dyslipidemias/drug therapy , History, 20th Century , History, 21st Century , Humans , Hypolipidemic Agents/therapeutic use , Lipids/blood , Preventive Health Services/history , Risk FactorsABSTRACT
Unfortunately, many patients as well as the medical community, continue to rely on coronary revascularization procedures and cardioprotective medications as a first-line strategy to stabilize or favorably modify established risk factors and the course of coronary artery disease. However, these therapies do not address the root of the problem, that is, the most proximal risk factors for heart disease, including unhealthy dietary practices, physical inactivity, and cigarette smoking. We argue that more emphasis must be placed on novel approaches to embrace current primary and secondary prevention guidelines, which requires attacking conventional risk factors and their underlying environmental causes. The impact of lifestyle on the risk of cardiovascular disease has been well established in clinical trials, but these results are often overlooked and underemphasized. Considerable data also strongly support the role of lifestyle intervention to improve glucose and insulin homeostasis, as well as physical inactivity and/or low aerobic fitness. Accordingly, intensive diet and exercise interventions can be highly effective in facilitating coronary risk reduction, complementing and enhancing medications, and in some instances, even outperforming drug therapy.
Subject(s)
Diet , Dyslipidemias/therapy , Exercise/physiology , Lipids/blood , Cardiovascular Diseases/blood , Cardiovascular Diseases/etiology , Cardiovascular Diseases/prevention & control , Dyslipidemias/blood , Dyslipidemias/history , History, 21st Century , Humans , Life Style , Motor Activity/physiology , Risk FactorsABSTRACT
Several decades ago, fibrates were approved for the treatment of dyslipidemia, whereas thiazolidinediones were screened in animal models to improve glucose homeostasis and were subsequently developed for the treatment of type 2 diabetes mellitus. Relatively recently, these drugs were found to act via peroxisome proliferator-activated receptors, nuclear receptors that control lipid metabolism and glucose homeostasis. In this historical perspective, we discuss the history of discovery of the peroxisome proliferator-activated receptors, from the clinical development of their agonists to the subsequent discovery of these receptors and their mechanisms of action, to finally evoke possibilities of targeted pharmacology for future development of selective peroxisome proliferator-activated receptor modulators.
Subject(s)
Clofibric Acid/history , Diabetes Mellitus, Type 2/history , Dyslipidemias/history , Hypoglycemic Agents/history , Hypolipidemic Agents/history , Peroxisome Proliferator-Activated Receptors/history , Thiazolidinediones/history , Animals , Blood Glucose/drug effects , Clofibric Acid/therapeutic use , Diabetes Mellitus, Type 2/drug therapy , Drug Discovery/history , Dyslipidemias/drug therapy , History, 20th Century , History, 21st Century , Humans , Hypoglycemic Agents/therapeutic use , Hypolipidemic Agents/therapeutic use , Lipid Metabolism/drug effects , Peroxisome Proliferator-Activated Receptors/agonists , Thiazolidinediones/therapeutic use , Treatment OutcomeABSTRACT
Metabolic syndrome--a cluster of metabolic diseases and hypertension--is not a new disease. It has been present in the upper classes of all highly developed cultures suffering from over-nutrition and limited physical activity. In the medical literature, it can be found in Renaissance and Baroque times. We are presently experiencing a global tsunami of this syndrome as over-nutrition and lack of movement are typical for large groups of the population. The current definition of metabolic syndrome of the American Heart Association/National Heart, Lung and Blood Institute and the International Diabetes Federation incorporates the quartet central obesity, hypertension, increased blood sugar and dyslipidemia (hypertriglyceridemia, low HDL cholesterol). Thus, simple, collective diagnostics and therapy for this finely meshed group of diseases together with its risk factors is possible.